tiprankstipranks
Advertisement
Advertisement

GANX Stock Latest News

Is GANX a Buy, Before Earnings?
Pre-EarningsIs GANX a Buy, Before Earnings?
8d ago
GANX
Buy Rating Reaffirmed on Encouraging GT-02287 Parkinson’s Data and Upcoming Catalysts; 12‑Month Price Target Maintained at $7
PremiumRatings
Buy Rating Reaffirmed on Encouraging GT-02287 Parkinson’s Data and Upcoming Catalysts; 12‑Month Price Target Maintained at $7
11d ago
GANX
Gain Therapeutics price target lowered to $8 from $10 at Roth Capital
PremiumThe Fly
Gain Therapeutics price target lowered to $8 from $10 at Roth Capital
13d ago
GANX
Gain Therapeutics reports Q1 EPS (13c), consensus (14c)
PremiumThe Fly
Gain Therapeutics reports Q1 EPS (13c), consensus (14c)
14d ago
GANX
Gain Therapeutics management to meet with Maxim
PremiumThe Fly
Gain Therapeutics management to meet with Maxim
1M ago
GANX
Reiterating Buy on Gain Therapeutics: Promising GT-02287 Parkinson’s Data and Diversified GCase Pipeline Support $8 Target
PremiumRatingsReiterating Buy on Gain Therapeutics: Promising GT-02287 Parkinson’s Data and Diversified GCase Pipeline Support $8 Target
2M ago
GANX
Gain Therapeutics reports Q4 EPS (61c), consensus (14c)
Premium
The Fly
Gain Therapeutics reports Q4 EPS (61c), consensus (14c)
2M ago
GANX
Gain Therapeutics Reports Promising GT-02287 Parkinson’s Data
Premium
Company Announcements
Gain Therapeutics Reports Promising GT-02287 Parkinson’s Data
2M ago
8K
GANX
Gain announces presentations on Phase 1b clinical study of GT-02287
PremiumThe Fly
Gain announces presentations on Phase 1b clinical study of GT-02287
2M ago
GANX
Gain Therapeutics, Inc. (GANX) Q4 Earnings Cheat Sheet
PremiumPre-Earnings
Gain Therapeutics, Inc. (GANX) Q4 Earnings Cheat Sheet
2M ago
GANX
Gain Therapeutics provides regulatory update on GT-02287
PremiumThe Fly
Gain Therapeutics provides regulatory update on GT-02287
2M ago
GANX
Buy Rating on Gain Therapeutics Driven by Validated Mechanism, Compelling Phase 1b Parkinson’s Data, and Attractive Risk‑Reward Despite Near‑Term Financing Needs
PremiumRatings
Buy Rating on Gain Therapeutics Driven by Validated Mechanism, Compelling Phase 1b Parkinson’s Data, and Attractive Risk‑Reward Despite Near‑Term Financing Needs
5M ago
GANX
Maintaining Buy on Gain Therapeutics: Strong GCase Biology, Validated GluSph Biomarker, and Favorable Risk-Reward for GT-02287 in Parkinson’s Disease
PremiumRatingsMaintaining Buy on Gain Therapeutics: Strong GCase Biology, Validated GluSph Biomarker, and Favorable Risk-Reward for GT-02287 in Parkinson’s Disease
5M ago
GANX
Gain Therapeutics provides additional data from Phase 1b study of GT-02287
Premium
The Fly
Gain Therapeutics provides additional data from Phase 1b study of GT-02287
5M ago
GANX
Gain Therapeutics: Attractive Upside on GT-02287 Parkinson’s Data and Upcoming KOL Catalyst Supports Buy Rating
Premium
Ratings
Gain Therapeutics: Attractive Upside on GT-02287 Parkinson’s Data and Upcoming KOL Catalyst Supports Buy Rating
5M ago
GANX
Gain Therapeutics holds a conference call
PremiumThe Fly
Gain Therapeutics holds a conference call
5M ago
GANX
Gain Therapeutics price target raised to $10 from $6 at Roth Capital
PremiumThe Fly
Gain Therapeutics price target raised to $10 from $6 at Roth Capital
5M ago
GANX
Clinical and Mechanistic De-Risking of GT-02287 Underpins Buy Rating on Gain Therapeutics (GANX)
PremiumRatings
Clinical and Mechanistic De-Risking of GT-02287 Underpins Buy Rating on Gain Therapeutics (GANX)
5M ago
GANX
Reiterating Buy on Gain Therapeutics: Promising GT-02287 Biomarker Data and Efficient Clinical Path Support Disease‑Modifying Potential in Parkinson’s
PremiumRatings
Reiterating Buy on Gain Therapeutics: Promising GT-02287 Biomarker Data and Efficient Clinical Path Support Disease‑Modifying Potential in Parkinson’s
5M ago
GANX
Gain Therapeutics Reports Encouraging Phase 1b Parkinson’s Data
PremiumCompany AnnouncementsGain Therapeutics Reports Encouraging Phase 1b Parkinson’s Data
5M ago
8K
GANX
Gain Therapeutic announces Phase 1b study of GT-02287 met prespecified endpoint
Premium
The Fly
Gain Therapeutic announces Phase 1b study of GT-02287 met prespecified endpoint
5M ago
GANX
Buy Rating for Gain Therapeutics Driven by Promising GT-02287 Developments and Upcoming Clinical Data
Premium
Ratings
Buy Rating for Gain Therapeutics Driven by Promising GT-02287 Developments and Upcoming Clinical Data
6M ago
GANX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >